Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CytomX Therapeutics, Inc. (CTMX)
USD3.68
+0.02 (+0.41%)
US NASDAQ Healthcare Biotechnology
Address
151 Oyster Point Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Sean A. McCarthy
Website
cytomx.com
IPO
2015-10-08
CIK 1501989 ISIN US23284F1057
Description
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
News Sentiment (7d)
Based on only 1 article — low confidence
- CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.68
+0.02 (+0.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
2.08
Float Shares
148.11M
Free Float %
87.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.02% | -6.54% | -12.07% | -28.91% | -8.75% | -9.39% | +81.22% | +116.85% | -51.20% | -61.82% | -70.08% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (21 ratings, all time)
Buy
Price Targets & DCF
Current price
3.68
Low
10.00
+172.1%
Consensus
11.50
+212.9%
Median
10.50
+185.7%
High
16.00
+335.4%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
14.00
+281.0%
|
| Last Year | 9 |
9.17
+149.5%
|
| All Time | 20 |
6.38
+73.6%
|
Quality scores
Altman Z-Score
7.19
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-44.8% Q1'26: -79.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-139.5% Q1'26: -137.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-118.1% Q1'26: -249.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-29.4% Q1'26: -191.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +329.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+62.8% Q1'26: +103.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.20× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 6 Rev. Ana. 7 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.71M
est: 7.59M (+1.6%)
|
15.04M
est: 10.43M (+44.2%)
|
71.62M
est: 57.17M (+25.3%)
|
59.50M
est: 63.73M (-6.6%)
|
57.49M
est: 67.28M (-14.5%)
|
68.43M
est: 99.93M (-31.5%)
|
37.31M
est: 69.41M (-46.2%)
|
53.16M
est: 72.04M (-26.2%)
|
101.21M
est: 119.57M (-15.4%)
|
138.10M
est: 115.66M (+19.4%)
|
76.20M
est: 82.92M (-8.1%)
|
22.95M
8.65M – 49.81M
-72.3% YoY
|
19.29M
9.10M – 32.53M
-16.0% YoY
|
38.34M
12.88M – 77.41M
+98.8% YoY
|
56.13M
18.85M – 113.34M
+46.4% YoY
|
204.16M
68.58M – 412.26M
+263.8% YoY
|
| EBITDA |
-32.43M
est: -4.32M (-650.1%)
|
-57.85M
est: -5.94M (-873.2%)
|
-41.97M
est: -32.57M (-28.8%)
|
-75.99M
est: -54.19M (-40.2%)
|
-100.06M
est: -93.23M (-7.3%)
|
-77.97M
est: -96.20M (+19.0%)
|
-113.34M
est: -39.55M (-186.6%)
|
-98.89M
est: -87.12M (-13.5%)
|
-4.31M
est: -50.80M (+91.5%)
|
26.76M
est: -49.14M (+154.5%)
|
-20.99M
est: -35.23M (+40.4%)
|
-9.75M
-21.16M – -3.67M
+72.3% YoY
|
-8.19M
-13.82M – -3.87M
+16.0% YoY
|
-16.29M
-32.89M – -5.47M
-98.8% YoY
|
-23.84M
-48.15M – -8.01M
-46.4% YoY
|
-86.73M
-175.15M – -29.14M
-263.8% YoY
|
| EBIT |
-33.63M
est: -4.38M (-668.7%)
|
-57.23M
est: -6.02M (-851.3%)
|
-43.61M
est: -32.97M (-32.3%)
|
-77.87M
est: -61.70M (-26.2%)
|
-102.67M
est: -104.10M (+1.4%)
|
-80.54M
est: -106.32M (+24.2%)
|
-116.04M
est: -40.02M (-189.9%)
|
-101.34M
est: -90.22M (-12.3%)
|
-6.48M
est: -52.05M (+87.5%)
|
25.00M
est: -50.35M (+149.6%)
|
-22.36M
est: -36.10M (+38.0%)
|
-9.99M
-21.68M – -3.77M
+72.3% YoY
|
-8.40M
-14.16M – -3.96M
+16.0% YoY
|
-16.69M
-33.70M – -5.61M
-98.8% YoY
|
-24.43M
-49.34M – -8.21M
-46.4% YoY
|
-88.87M
-179.46M – -29.85M
-263.8% YoY
|
| Net Income |
-35.37M
est: -184.18M (+80.8%)
|
-58.90M
est: -145.08M (+59.4%)
|
-43.10M
est: -136.66M (+68.5%)
|
-84.60M
est: -65.45M (-29.3%)
|
-102.24M
est: -95.46M (-7.1%)
|
-64.82M
est: -69.64M (+6.9%)
|
-115.87M
est: -106.93M (-8.4%)
|
-99.32M
est: -42.24M (-135.1%)
|
-569.0K
est: 11.09M (-105.1%)
|
31.87M
est: -14.32M (+322.5%)
|
-17.37M
est: -1.93M (-800.4%)
|
-91.00M
-91.34M – -40.86M
-4,617.8% YoY
|
-76.00M
-86.36M – -65.63M
+16.5% YoY
|
-94.40M
-110.10M – -47.61M
-24.2% YoY
|
-80.69M
-187.62M – -11.03M
+14.5% YoY
|
-14.48M
-33.68M – -1.98M
+82.1% YoY
|
| SGA |
12.56M
est: 4.39M (+186.0%)
|
19.87M
est: 6.04M (+229.1%)
|
25.61M
est: 33.09M (-22.6%)
|
33.51M
est: 27.63M (+21.3%)
|
36.77M
est: 36.37M (+1.1%)
|
36.03M
est: 78.27M (-54.0%)
|
39.16M
est: 40.18M (-2.5%)
|
42.85M
est: 45.51M (-5.9%)
|
30.02M
est: 65.98M (-54.5%)
|
29.73M
est: 63.82M (-53.4%)
|
29.84M
est: 45.75M (-34.8%)
|
12.66M
4.77M – 27.49M
-72.3% YoY
|
10.64M
5.02M – 17.95M
-16.0% YoY
|
21.15M
7.11M – 42.72M
+98.8% YoY
|
30.97M
10.40M – 62.54M
+46.4% YoY
|
112.65M
37.84M – 227.48M
+263.8% YoY
|
| EPS |
-1.00
est: -2.17 (+54.0%)
|
-1.63
est: -1.71 (+4.8%)
|
-1.16
est: -1.61 (+28.1%)
|
-2.03
est: -1.75 (-16.0%)
|
-2.26
est: -1.94 (-16.4%)
|
-0.71
est: -0.91 (+22.1%)
|
-1.26
est: -1.26 (+0.1%)
|
-1.48
est: -1.29 (-14.7%)
|
-0.01
est: 0.13 (-105.7%)
|
0.38
est: -0.04 (+978.2%)
|
-0.15
est: -0.03 (-436.3%)
|
-0.49
-0.66 – -0.30
-1,644.6% YoY
|
-0.56
-0.63 – -0.48
-14.6% YoY
|
-0.50
-0.80 – -0.35
+10.9% YoY
|
-0.59
-1.36 – -0.08
-17.4% YoY
|
-0.11
-0.24 – -0.01
+82.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-109.68M
OE per share TTM
-0.67
Owner's Yield
-15.47%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
26.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
26
Total invested
7.28M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVF Inc. | 6.60M | 10.10% | — | — | — | 6.60M | CO | Delaware | 2022-07-29 | ↗ |
| 2 | BVF Partners L.P. | 6.60M | 10.10% | — | — | — | 6.60M | IA, PN | Delaware | 2022-07-29 | ↗ |
| 3 | Mark N. Lampert | 6.60M | 10.10% | — | — | — | 6.60M | IN | Delaware | 2022-07-29 | ↗ |
| 4 | Steven A. Cohen | 6.31M | 4.00% | — | 6.31M | — | 6.31M | IN | Citizenship or place of organization United States | 2022-02-14 | ↗ |
| 5 | Point72 Asset Management, L.P. | 6.30M | 4.00% | — | 6.30M | — | 6.30M | PN | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 6 | Point72 Capital Advisors, Inc. | 6.30M | 4.00% | — | 6.30M | — | 6.30M | CO | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 7 | BVF GP Holdings LLC | 6.17M | 9.40% | — | — | — | 6.17M | OO | Delaware | 2022-07-29 | ↗ |
| 8 | RTW Investments, LP | 6.03M | 9.20% | — | 6.03M | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 9 | Roderick Wong | 6.03M | 9.20% | — | 6.03M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 10 | Bihua Chen | 5.75M | 7.38% | — | 5.75M | — | — | IN | Cayman Islands | 2024-05-13 | ↗ |
| 11 | Cormorant Asset Management, LP | 5.75M | 7.38% | — | 5.75M | — | — | PN | Cayman Islands | 2024-05-13 | ↗ |
| 12 | Cormorant Global Healthcare GP, LLC | 5.75M | 7.38% | — | 5.75M | — | — | OO | Cayman Islands | 2024-05-13 | ↗ |
| 13 | Cormorant Global Healthcare Master Fund, LP | 5.75M | 7.38% | — | 5.75M | — | — | PN | Cayman Islands | 2024-05-13 | ↗ |
| 14 | The Vanguard Group - 23-1945930 | 5.11M | 7.83% | — | 99.5K | 4.99M | 122.3K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 15 | 00-0000000 | 4.16M | 5.30% | — | 4.16M | — | 4.16M | CO | Cayman Islands | 2024-05-22 | ↗ |
| 16 | EIN #00-0000000 | 4.16M | 5.30% | — | 4.16M | — | 4.16M | IA, HC | Jersey, Channel Islands | 2024-05-22 | ↗ |
| 17 | RTW Master Fund, Ltd. | 3.88M | 5.95% | — | 3.88M | — | 3.88M | CO | Delaware | 2021-12-08 | ↗ |
| 18 | BVF I GP LLC | 3.54M | 5.40% | — | — | — | 3.54M | OO | Delaware | 2022-07-29 | ↗ |
| 19 | Biotechnology Value Fund, L.P. | 3.54M | 5.40% | — | — | — | 3.54M | PN | Delaware | 2022-07-29 | ↗ |
| 20 | BVF II GP LLC | 2.62M | 4.00% | — | — | — | 2.62M | OO | Delaware | 2022-07-29 | ↗ |
| 21 | Biotechnology Value Fund II, L.P. | 2.62M | 4.00% | — | — | — | 2.62M | PN | Delaware | 2022-07-29 | ↗ |
| 22 | (1) BlackRock, Inc. | 1.83M | 2.80% | 1.83M | — | 1.83M | — | HC | Delaware | 2022-07-08 | ↗ |
| 23 | BVF Partners OS Ltd. | 319.7K | 1.00% | — | — | — | 319.7K | CO | Delaware | 2022-07-29 | ↗ |
| 24 | Biotechnology Value Trading Fund OS LP | 319.7K | 1.00% | — | — | — | 319.7K | PN | Delaware | 2022-07-29 | ↗ |
| 25 | Cubist Systematic Strategies, LLC | 9.3K | 4.00% | — | 9.3K | — | 9.3K | OO | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 26 | 2. | 8.8K | 12.00% | 8.8K | — | — | — | IA | New York | 2022-02-01 | ↗ |
| 27 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-02-14 | ↗ |
| 28 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 29 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 30 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
26
-104 vs prev Q
New positions
8
Closed positions
105
Increased
13
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 700.0K +700.0K (+100.0%) | 2.98B +3.0B (+100.0%) | 0.42% +0.424 pp | 0.88% +0.880 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 24.69M +9.3M (+60.4%) | 105.17M +56.1M (+114.1%) | 14.96% +5.631 pp | 0.01% +0.003 pp | USD3.28 +29.9% | 41 qtrs — |
| 3 | VR ADVISER, LLC | 15.56M +— (+0.0%) | 66.29M +16.7M (+33.5%) | 9.43% +0.000 pp | 3.27% +0.480 pp | USD2.36 +80.5% | 3 qtrs — |
| 4 | PERCEPTIVE ADVISORS LLC | 9.68M +— (+0.0%) | 41.24M +10.4M (+33.5%) | 5.87% +0.000 pp | 0.74% -0.157 pp | USD2.53 +68.4% | 3 qtrs — |
| 5 | KYNAM CAPITAL MANAGEMENT, LP | 8.97M +5.3M (+145.9%) | 38.20M +26.6M (+228.4%) | 5.43% +3.224 pp | 2.44% +1.574 pp | USD3.60 +18.3% | 3 qtrs — |
| 6 | VANGUARD GROUP INC | 8.48M -472.2K (-5.3%) | 36.11M +7.6M (+26.5%) | 5.14% -0.286 pp | 0.00% +0.000 pp | USD6.30 -32.4% | 41 qtrs — |
| 7 | COMMODORE CAPITAL LP | 7.69M +— (+0.0%) | 32.77M +8.2M (+33.5%) | 4.66% +0.000 pp | 2.18% +0.983 pp | USD2.27 +87.7% | 3 qtrs — |
| 8 | POINT72 ASSET MANAGEMENT, L.P. | 5.19M +1.1M (+27.6%) | 22.11M +9.1M (+70.3%) | 3.15% +0.679 pp | 0.02% +0.003 pp | USD2.38 +79.0% | 5 qtrs — |
| 9 | STATE STREET CORP | 5.14M +4.5M (+697.1%) | 21.90M +19.8M (+964.4%) | 3.12% +2.725 pp | 0.00% +0.001 pp | USD4.30 -0.9% | 41 qtrs — |
| 10 | BAKER BROS. ADVISORS LP | 4.25M +— (+0.0%) | 18.11M +4.5M (+33.5%) | 2.58% +0.000 pp | 0.11% +0.008 pp | USD2.44 +74.6% | 3 qtrs — |
| 11 | ADAR1 CAPITAL MANAGEMENT, LLC | 4.18M +137.4K (+3.4%) | 17.82M +4.9M (+38.1%) | 2.53% +0.083 pp | 1.31% +0.096 pp | USD2.54 +67.7% | 8 qtrs — |
| 12 | FINANCIAL ENGINES ADVISORS L.L.C. | 3.83M +2.4M (+177.2%) | 16.31M +11.9M (+270.1%) | 2.32% +1.483 pp | 0.03% +0.023 pp | USD3.87 +10.1% | 2 qtrs — |
| 13 | BLACKROCK, INC. | 3.67M +1.3M (+54.1%) | 15.63M +8.0M (+105.7%) | 2.22% +0.780 pp | 0.00% +0.000 pp | USD2.62 +62.6% | 6 qtrs — |
| 14 | ORBIMED ADVISORS LLC | 3.53M -4.9M (-58.3%) | 15.02M -12.0M (-44.4%) | 2.14% -2.991 pp | 0.31% -0.328 pp | USD2.27 +87.7% | 3 qtrs — |
| 15 | IKARIAN CAPITAL, LLC | 3.17M -200.0K (-5.9%) | 13.52M +2.8M (+25.6%) | 1.92% -0.121 pp | 1.06% -0.031 pp | USD3.19 +33.5% | 2 qtrs — |
| 16 | VIVO CAPITAL, LLC | 2.88M +— (+0.0%) | 12.29M +3.1M (+33.5%) | 1.75% +0.000 pp | 0.79% +0.054 pp | USD2.27 +87.7% | 3 qtrs — |
| 17 | EVERSEPT PARTNERS, LP | 2.51M +2.5M (+100.0%) | 10.68M +10.7M (+100.0%) | 1.52% +1.519 pp | 0.54% +0.538 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 18 | GOLDMAN SACHS GROUP INC | 2.46M +2.0M (+449.6%) | 10.48M +9.1M (+634.0%) | 1.49% +1.220 pp | 0.00% +0.001 pp | USD4.05 +5.2% | 8 qtrs — |
| 19 | WOODLINE PARTNERS LP | 2.34M +— (+0.0%) | 9.96M +2.5M (+33.5%) | 1.42% +0.000 pp | 0.04% +0.004 pp | USD1.11 +283.8% | 6 qtrs — |
| 20 | TWO SIGMA INVESTMENTS, LP | 1.56M +831.1K (+113.9%) | 6.65M +4.3M (+185.6%) | 0.95% +0.504 pp | 0.01% +0.006 pp | USD3.62 +17.7% | 36 qtrs — |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 1.53M -43.6K (-2.8%) | 6.50M +1.5M (+29.8%) | 0.92% -0.026 pp | 0.00% +0.000 pp | USD5.47 -22.1% | 41 qtrs — |
| 22 | DIMENSIONAL FUND ADVISORS LP | 1.29M +838.5K (+185.9%) | 5.49M +4.1M (+281.7%) | 0.78% +0.508 pp | 0.00% +0.001 pp | USD3.76 +13.3% | 3 qtrs — |
| 23 | MARSHALL WACE, LLP | 1.16M +51.9K (+4.7%) | 4.93M +1.4M (+39.8%) | 0.70% +0.032 pp | 0.00% +0.001 pp | USD2.30 +85.2% | 4 qtrs — |
| 24 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.06M +938.6K (+766.2%) | 4.52M +4.1M (+1,056.8%) | 0.64% +0.569 pp | 0.00% +0.004 pp | USD4.14 +2.9% | 15 qtrs — |
| 25 | STEMPOINT CAPITAL LP | 1.04M +1.0M (+100.0%) | 4.41M +4.4M (+100.0%) | 0.63% +0.628 pp | 0.76% +0.757 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 26 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 981.6K +714.1K (+267.0%) | 4.18M +3.3M (+390.1%) | 0.59% +0.433 pp | 0.00% +0.000 pp | USD3.69 +15.4% | 27 qtrs — |
| 27 | BALYASNY ASSET MANAGEMENT L.P. | 900.0K +— (+0.0%) | 3.83M +963.0K (+33.5%) | 0.55% +0.000 pp | 0.00% +0.001 pp | USD3.19 +33.5% | 2 qtrs — |
| 28 | BOOTHBAY FUND MANAGEMENT, LLC | 894.7K -342.4K (-27.7%) | 3.81M -134.9K (-3.4%) | 0.54% -0.208 pp | 0.06% -0.001 pp | USD3.19 +33.5% | 2 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 876.3K -128.9K (-12.8%) | 3.73M +526.4K (+16.4%) | 0.53% -0.248 pp | 0.00% +0.000 pp | USD3.18 +34.0% | 41 qtrs — |
| 30 | ACADIAN ASSET MANAGEMENT LLC | 856.1K +202.3K (+31.0%) | 3.64M +1.6M (+74.9%) | 0.52% +0.123 pp | 0.01% +0.002 pp | USD2.88 +47.9% | 28 qtrs — |
| 31 | EXOME ASSET MANAGEMENT LLC | 745.3K +— (+0.0%) | 3.17M +797.5K (+33.5%) | 0.45% +0.000 pp | 1.52% +0.078 pp | USD3.19 +33.5% | 2 qtrs — |
| 32 | JANE STREET GROUP, LLC | 607.2K +205.9K (+51.3%) | 2.59M +1.3M (+102.0%) | 0.37% +0.125 pp | 0.00% +0.000 pp | USD3.53 +20.7% | 13 qtrs — |
| 33 | ASSENAGON ASSET MANAGEMENT S.A. | 592.7K -137.3K (-18.8%) | 2.52M +196.3K (+8.4%) | 0.36% -0.083 pp | 0.00% +0.000 pp | USD1.25 +240.8% | 14 qtrs — |
| 34 | FIRST TRUST ADVISORS LP | 423.2K +21.3K (+5.3%) | 1.80M +520.7K (+40.6%) | 0.26% +0.013 pp | 0.00% +0.000 pp | USD3.24 +31.5% | 2 qtrs — |
| 35 | NORTHERN TRUST CORP | 415.2K +25.5K (+6.5%) | 1.77M +525.6K (+42.3%) | 0.25% +0.015 pp | 0.00% +0.000 pp | USD5.20 -18.1% | 41 qtrs — |
| 36 | MORGAN STANLEY | 401.2K +81.9K (+25.7%) | 1.71M +690.5K (+67.8%) | 0.24% +0.050 pp | 0.00% +0.000 pp | USD2.49 +71.1% | 41 qtrs — |
| 37 | SILVERARC CAPITAL MANAGEMENT, LLC | 386.0K +386.0K (+100.0%) | 1.64M +1.6M (+100.0%) | 0.23% +0.234 pp | 0.23% +0.228 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 38 | SCHULHOFF & CO INC | 374.9K +374.9K (+100.0%) | 1.60M +1.6M (+100.0%) | 0.23% +0.227 pp | 0.67% +0.672 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 39 | UBS GROUP AG | 370.7K +340.6K (+1,128.9%) | 1.58M +1.5M (+1,541.1%) | 0.22% +0.206 pp | 0.00% +0.000 pp | USD3.99 +6.8% | 41 qtrs — |
| 40 | CITADEL ADVISORS LLC | 342.3K -1.5M (-81.0%) | 1.46M -4.3M (-74.6%) | 0.21% -0.884 pp | 0.00% -0.001 pp | USD3.15 +35.2% | 32 qtrs — |
| 41 | BARCLAYS PLC | 336.5K +335.0K (+22,485.6%) | 1.43M +1.4M (+30,061.9%) | 0.20% +0.203 pp | 0.00% +0.000 pp | USD4.26 +0.0% | 4 qtrs — |
| 42 | TWO SIGMA ADVISERS, LP | 335.5K +295.5K (+738.8%) | 1.43M +1.3M (+1,020.2%) | 0.20% +0.179 pp | 0.00% +0.003 pp | USD4.13 +3.1% | 2 qtrs — |
| 43 | BANK OF NEW YORK MELLON CORP | 328.2K +75.6K (+29.9%) | 1.40M +592.4K (+73.5%) | 0.20% +0.046 pp | 0.00% +0.000 pp | USD3.10 +37.4% | 41 qtrs — |
| 44 | RAYMOND JAMES FINANCIAL INC | 317.0K +23.4K (+8.0%) | 1.35M +413.8K (+44.2%) | 0.19% +0.014 pp | 0.00% +0.000 pp | USD2.45 +73.9% | 3 qtrs — |
| 45 | MILLENNIUM MANAGEMENT LLC | 289.7K -1.1M (-79.1%) | 1.23M -3.2M (-72.1%) | 0.18% -0.665 pp | 0.00% -0.001 pp | USD2.90 +46.9% | 39 qtrs — |
| 46 | RAFFERTY ASSET MANAGEMENT, LLC | 273.6K +273.6K (+100.0%) | 1.17M +1.2M (+100.0%) | 0.17% +0.166 pp | 0.00% +0.004 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 47 | AMERIPRISE FINANCIAL INC | 229.6K +71.3K (+45.0%) | 989.0K +483.9K (+95.8%) | 0.14% +0.043 pp | 0.00% +0.000 pp | USD3.52 +21.0% | 2 qtrs — |
| 48 | PRELUDE CAPITAL MANAGEMENT, LLC | 206.5K +— (+0.0%) | 879.8K +221.0K (+33.5%) | 0.13% +0.000 pp | 0.06% +0.013 pp | USD3.19 +33.5% | 2 qtrs — |
| 49 | EAM INVESTORS, LLC | 203.8K +203.8K (+100.0%) | 868.3K +868.3K (+100.0%) | 0.12% +0.124 pp | 0.10% +0.097 pp | USD4.26 +0.0% | 3 qtrs — |
| 50 | HIGHVISTA STRATEGIES LLC | 193.9K -63.2K (-24.6%) | 826.2K +5.9K (+0.7%) | 0.12% -0.038 pp | 0.21% +0.012 pp | USD3.19 +33.5% | 2 qtrs — |
| 51 | SEI INVESTMENTS CO | 124.1K +124.1K (+100.0%) | 528.8K +528.8K (+100.0%) | 0.08% +0.075 pp | 0.00% +0.001 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 52 | LPL FINANCIAL LLC | 113.4K +26.8K (+30.9%) | 483.3K +206.8K (+74.8%) | 0.07% +0.016 pp | 0.00% +0.000 pp | USD2.63 +62.0% | 15 qtrs — |
| 53 | CANADA PENSION PLAN INVESTMENT BOARD | 104.2K +104.2K (+100.0%) | 443.9K +443.9K (+100.0%) | 0.06% +0.063 pp | 0.00% +0.000 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 54 | ASPIRE GROWTH PARTNERS LLC | 102.3K +— (+0.0%) | 435.6K +109.4K (+33.5%) | 0.06% +0.000 pp | 0.30% +0.064 pp | USD0.95 +348.4% | 5 qtrs — |
| 55 | PROFUND ADVISORS LLC | 98.6K +98.6K (+100.0%) | 420.2K +420.2K (+100.0%) | 0.06% +0.060 pp | 0.01% +0.013 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 56 | CITIGROUP INC | 96.3K +88.6K (+1,142.0%) | 410.3K +385.6K (+1,558.5%) | 0.06% +0.054 pp | 0.00% +0.000 pp | USD4.17 +2.2% | 2 qtrs — |
| 57 | OMERS ADMINISTRATION CORP | 87.8K +87.8K (+100.0%) | 374.0K +374.0K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.003 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 58 | GSA CAPITAL PARTNERS LLP | 81.9K -454.1K (-84.7%) | 349.0K -1.4M (-79.6%) | 0.05% -0.275 pp | 0.03% -0.113 pp | USD0.66 +545.5% | 11 qtrs — |
| 59 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 80.0K +— (+0.0%) | 340.8K +85.6K (+33.5%) | 0.05% +0.000 pp | 0.20% -0.042 pp | USD0.97 +339.2% | 5 qtrs — |
| 60 | HRT FINANCIAL LP | 71.9K +71.9K (+100.0%) | 306.0K +306.0K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.001 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 61 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 68.7K -19.9K (-22.4%) | 292.6K +10.1K (+3.6%) | 0.04% -0.012 pp | 0.00% +0.000 pp | USD2.04 +108.8% | 41 qtrs — |
| 62 | MILLER FINANCIAL SERVICES LLC | 68.0K +1.0K (+1.5%) | 289.7K +76.0K (+35.5%) | 0.04% +0.001 pp | 0.34% +0.093 pp | USD1.44 +195.8% | 5 qtrs — |
| 63 | VIRTUS INVESTMENT ADVISERS, INC. | 63.5K +63.5K (+100.0%) | 270.5K +270.5K (+100.0%) | 0.04% +0.039 pp | 0.07% +0.074 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 64 | SKOPOS LABS, INC. | 61.5K -25.7K (-29.5%) | 257.6K -20.5K (-7.4%) | 0.04% -0.016 pp | 0.01% -0.018 pp | USD3.19 +33.5% | 2 qtrs — |
| 65 | CONGRESS PARK CAPITAL LLC | 58.9K -45.0K (-43.3%) | 251.0K -80.5K (-24.3%) | 0.04% -0.027 pp | 0.07% -0.028 pp | USD1.51 +182.1% | 12 qtrs — |
| 66 | MERIT FINANCIAL GROUP, LLC | 53.2K +— (+0.0%) | 226.8K +57.0K (+33.5%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD3.19 +33.5% | 2 qtrs — |
| 67 | SG AMERICAS SECURITIES, LLC | 53.1K +53.1K (+100.0%) | 226.0K +226.0K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 68 | HUDSON BAY CAPITAL MANAGEMENT LP | 51.0K +51.0K (+100.0%) | 217.2K +217.2K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.001 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 69 | SQUAREPOINT OPS LLC | 49.9K +2.2K (+4.5%) | 212.6K +60.3K (+39.6%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD2.36 +80.5% | 3 qtrs — |
| 70 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 48.0K +— (+0.0%) | 204.5K +51.4K (+33.5%) | 0.03% +0.000 pp | 0.00% +0.001 pp | USD2.27 +87.7% | 3 qtrs — |
| 71 | XTX TOPCO LTD | 48.0K +18.7K (+63.9%) | 204.4K +111.0K (+118.8%) | 0.03% +0.011 pp | 0.01% +0.001 pp | USD3.05 +39.7% | 9 qtrs — |
| 72 | TOROSO INVESTMENTS, LLC | 45.8K -72.6K (-61.3%) | 195.0K -182.5K (-48.4%) | 0.03% -0.044 pp | 0.00% 0.000 pp | USD1.46 +191.8% | 15 qtrs — |
| 73 | FORMIDABLE ASSET MANAGEMENT, LLC | 45.8K -72.6K (-61.3%) | 195.0K -182.5K (-48.4%) | 0.03% -0.044 pp | 0.03% -0.031 pp | USD1.46 +191.8% | 15 qtrs — |
| 74 | BAADER BANK AKTIENGESELLSCHAFT | 45.0K +45.0K (+100.0%) | 191.7K +191.7K (+100.0%) | 0.03% +0.027 pp | 0.01% +0.013 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 75 | PRIVATE ADVISOR GROUP, LLC | 44.0K +— (+0.0%) | 187.4K +47.1K (+33.5%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD17.12 -75.1% | 39 qtrs — |
| 76 | J. GOLDMAN & CO LP | 37.0K +37.0K (+100.0%) | 157.6K +157.6K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.004 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 77 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 32.0K +32.0K (+100.0%) | 136.5K +136.5K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.004 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 78 | EMPOWERED FUNDS, LLC | 31.3K +31.3K (+100.0%) | 133.5K +133.5K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.001 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 79 | CAMBRIA INVESTMENT MANAGEMENT, L.P. | 31.3K +31.3K (+100.0%) | 133.5K +133.5K (+100.0%) | 0.02% +0.019 pp | 0.01% +0.008 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 80 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 27.6K +27.6K (+100.0%) | 117.6K +117.6K (+100.0%) | 0.02% +0.017 pp | 0.01% +0.009 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 81 | TRUVESTMENTS CAPITAL LLC | 27.4K +10.3K (+60.4%) | 116.8K +62.3K (+114.2%) | 0.02% +0.006 pp | 0.02% +0.011 pp | USD3.09 +37.9% | 3 qtrs — |
| 82 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 26.8K -174.0 (-0.6%) | 114.0K +28.1K (+32.7%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.51 +182.1% | 5 qtrs — |
| 83 | ENGINEERS GATE MANAGER LP | 26.5K +26.5K (+100.0%) | 113.1K +113.1K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.001 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 84 | MANGROVE PARTNERS | 26.3K +26.3K (+100.0%) | 111.9K +111.9K (+100.0%) | 0.02% +0.016 pp | 0.01% +0.009 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 85 | HB WEALTH MANAGEMENT, LLC | 25.0K +25.0K (+100.0%) | 106.5K +106.5K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.001 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 86 | TOWER RESEARCH CAPITAL LLC (TRC) | 24.8K +24.8K (+826,366.7%) | 105.6K +105.6K (+1,056,120.0%) | 0.02% +0.015 pp | 0.00% +0.003 pp | USD4.26 +0.0% | 27 qtrs — |
| 87 | JPMORGAN CHASE & CO | 24.4K +8.2K (+50.8%) | 103.8K +52.3K (+101.4%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD3.53 +20.7% | 37 qtrs — |
| 88 | SIMPLEX TRADING, LLC | 24.1K +24.1K (+100.0%) | 102.5K +102.5K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.000 pp | USD4.26 +0.0% | 1 qtrs NEW |
| 89 | JEFFERIES FINANCIAL GROUP INC. | 23.8K -29.2K (-55.1%) | 101.2K -67.6K (-40.0%) | 0.01% -0.018 pp | 0.00% 0.000 pp | USD3.19 +33.5% | 2 qtrs — |
| 90 | ETHOS FINANCIAL GROUP, LLC | 23.7K +— (+0.0%) | 100.9K +25.4K (+33.5%) | 0.01% +0.000 pp | 0.01% +0.002 pp | USD3.19 +33.5% | 2 qtrs — |
| 91 | MARINER, LLC | 22.2K +11.9K (+116.4%) | 94.5K +61.8K (+189.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD3.77 +13.0% | 2 qtrs — |
| 92 | INVESCO LTD. | 22.0K -450.0 (-2.0%) | 93.6K +22.1K (+30.9%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD2.61 +63.2% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 92 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Fidelity Disruptive Medicine ETF FMED | 0.91% | 420.0K | 0.50% |
| 2 | First Trust Dow Jones Select MicroCap Index Fund FDM | 0.86% | 2.25M | 0.65% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.77% | 442.6K | 0.65% |
| 4 | iShares Genomics Immunology and Healthcare ETF IDNA | 0.72% | 1.40M | 0.47% |
| 5 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.52% | 114.6K | 0.20% |
| 6 | Tema Oncology ETF CANC | 0.45% | 636.7K | 0.75% |
| 7 | Formidable ETF FORH | 0.38% | 82.9K | 1.19% |
| 8 | Global X - S&P Biotech ETF CURE.AX | 0.28% | 100.0K | 0.45% |
| 9 | State Street SPDR S&P Biotech ETF XBI | 0.28% | 30.03M | 0.35% |
| 10 | Barron's 400SM ETF BFOR | 0.18% | 402.7K | 0.65% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.75
Bullish
Ratio by volume
3.00
Bullish
Buys
11
Sells
4
Shares acquired
2.41M
Shares disposed
191.1K
Cash buys
—
Cash sales
4.00
Net activity
+2,218,937
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | Ogden Christopher | Officer | S-Sale | D | Common Stock | 19,323 | 6.42 | 124.1K | 296,948 | D | ↗ |
| 2026-03-17 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 118,969 | 6.42 | 764.1K | 1,078,922 | D | ↗ |
| 2026-03-17 | Chu Yu-Waye | Officer | S-Sale | D | Common Stock | 21,279 | 6.42 | 136.7K | 189,446 | D | ↗ |
| 2026-03-17 | BELVIN MARCIA | Officer | S-Sale | D | Common Stock | 31,492 | 6.42 | 202.3K | 300,760 | D | ↗ |
| 2026-02-02 | Ogden Christopher | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 316,271 | D | ↗ |
| 2026-02-02 | McCarthy Sean A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 980,000 | 6.09 | 5.97M | 980,000 | D | ↗ |
| 2026-02-02 | Lester Rachael | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | D | ↗ |
| 2026-02-02 | Chu Yu-Waye | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 210,725 | D | ↗ |
| 2026-02-02 | BELVIN MARCIA | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 332,252 | D | ↗ |
| 2025-11-06 | McCarthy Sean A. | Director / Officer | S-Sale | D | Class A Common Stock | 101,793 | 4.54 | 461.9K | 987,891 | D | ↗ |
| 2025-10-20 | Lester Rachael | Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 3.74 | 2.43M | 650,000 | D | ↗ |
| 2025-09-26 | Ogden Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 78,250 | 2.90 | 226.9K | 78,250 | D | ↗ |
| 2025-09-26 | McCarthy Sean A. | Director / Officer | A-Award | A | Performance Stock Units (PSUs) | 285,000 | 0.00 | — | 285,000 | D | ↗ |
| 2025-09-26 | Chu Yu-Waye | Officer | A-Award | A | Performance Stock Units (PSUs) | 43,750 | 0.00 | — | 43,750 | D | ↗ |
| 2025-09-26 | BELVIN MARCIA | Officer | A-Award | A | Performance Stock Units (PSUs) | 18,150 | 0.00 | — | 18,150 | D | ↗ |
| 2025-06-16 | Ogden Christopher | Officer | S-Sale | D | Common Stock | 10,614 | 2.69 | 28.5K | 226,271 | D | ↗ |
| 2025-06-16 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 55,511 | 2.69 | 149.3K | 1,089,684 | D | ↗ |
| 2025-06-16 | BELVIN MARCIA | Officer | S-Sale | D | Common Stock | 13,884 | 2.69 | 37.3K | 272,252 | D | ↗ |
| 2025-06-13 | Ogden Christopher | Officer | M-Exempt | D | Performance Stock Units | 37,500 | 0.00 | — | 0 | D | ↗ |
| 2025-06-13 | McCarthy Sean A. | Director / Officer | M-Exempt | A | Common Stock | 150,000 | 0.00 | — | 1,145,195 | D | ↗ |
| 2025-06-13 | BELVIN MARCIA | Officer | M-Exempt | D | Performance Stock Units | 37,500 | 0.00 | — | 0 | D | ↗ |
| 2025-06-11 | Young Matthew P. | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.82 | 107.2K | 38,000 | D | ↗ |
| 2025-06-11 | Su Zhen | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.82 | 107.2K | 38,000 | D | ↗ |
| 2025-06-11 | Mohindru Mani | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.82 | 107.2K | 38,000 | D | ↗ |
| 2025-06-11 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.82 | 107.2K | 38,000 | D | ↗ |
| 2025-06-11 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.82 | 107.2K | 38,000 | D | ↗ |
| 2025-06-11 | Gilbert Halley E | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.82 | 107.2K | 38,000 | D | ↗ |
| 2025-06-11 | Ashworth Alan | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 2.82 | 107.2K | 38,000 | D | ↗ |
| 2025-03-18 | ROWLAND LLOYD A | Officer | S-Sale | D | Common Stock | 10,203 | 0.60 | 6.1K | 120,594 | D | ↗ |
| 2025-03-18 | Ogden Christopher | Officer | S-Sale | D | Common Stock | 8,551 | 0.60 | 5.1K | 201,026 | D | ↗ |
| 2025-03-18 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 37,656 | 0.60 | 22.6K | 995,195 | D | ↗ |
| 2025-03-18 | Chu Yu-Waye | Officer | S-Sale | D | Common Stock | 4,025 | 0.60 | 2.4K | 135,725 | D | ↗ |
| 2025-03-18 | BELVIN MARCIA | Officer | S-Sale | D | Common Stock | 19,512 | 0.60 | 11.7K | 248,636 | D | ↗ |
| 2025-02-04 | Ogden Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 0.86 | 99.4K | 115,000 | D | ↗ |
| 2025-02-04 | McCarthy Sean A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 800,000 | 0.86 | 691.2K | 800,000 | D | ↗ |
| 2025-02-04 | Chu Yu-Waye | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 0.86 | 99.4K | 115,000 | D | ↗ |
| 2025-02-04 | BELVIN MARCIA | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 0.86 | 99.4K | 115,000 | D | ↗ |
| 2024-08-20 | ROWLAND LLOYD A | Officer | S-Sale | D | Common Stock | 4,181 | 1.23 | 5.1K | 130,797 | — | ↗ |
| 2024-08-20 | Ogden Christopher | Officer | M-Exempt | D | Performance Stock Units (PSUs) | 6,875 | 0.00 | — | 0 | — | ↗ |
| 2024-08-20 | McCarthy Sean A. | Director / Officer | M-Exempt | D | Performance Stock Units (PSUs) | 37,500 | 0.00 | — | 0 | — | ↗ |
| 2024-08-20 | Landau Jeffrey B | Officer | S-Sale | D | Common Stock | 4,181 | 1.23 | 5.1K | 119,056 | — | ↗ |
| 2024-08-20 | BELVIN MARCIA | Officer | M-Exempt | D | Performance Stock Units (PSUs) | 11,250 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | Ogden Christopher | Officer | A-Award | A | Common Stock | 17,500 | 0.00 | — | 103,186 | — | ↗ |
| 2024-05-15 | Young Matthew P. | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 1.96 | 74.5K | 38,000 | — | ↗ |
| 2024-05-15 | Su Zhen | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 1.96 | 74.5K | 38,000 | — | ↗ |
| 2024-05-15 | Mohindru Mani | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 1.98 | 75.2K | 38,000 | — | ↗ |
| 2024-05-15 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 1.96 | 74.5K | 38,000 | — | ↗ |
| 2024-05-15 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 1.96 | 74.5K | 38,000 | — | ↗ |
| 2024-05-15 | Gilbert Halley E | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 1.96 | 74.5K | 38,000 | — | ↗ |
| 2024-05-15 | Ashworth Alan | Director | A-Award | A | Stock Option (Right to Buy) | 38,000 | 1.96 | 74.5K | 38,000 | — | ↗ |
| 2024-03-26 | McCarthy Sean A. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 109,768 | 1.57 | 172.9K | 0 | — | ↗ |
| 2024-03-20 | Su Zhen | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-19 | ROWLAND LLOYD A | Officer | S-Sale | D | Common Stock | 5,268 | 2.09 | 11.0K | 117,728 | — | ↗ |
| 2024-03-19 | Ogden Christopher | Officer | S-Sale | D | Common Stock | 2,971 | 2.09 | 6.2K | 85,686 | — | ↗ |
| 2024-03-19 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 20,223 | 2.09 | 42.2K | 524,481 | — | ↗ |
| 2024-03-19 | Landau Jeffrey B | Officer | S-Sale | D | Common Stock | 6,562 | 2.09 | 13.7K | 110,060 | — | ↗ |
| 2024-03-19 | BELVIN MARCIA | Officer | S-Sale | D | Common Stock | 12,795 | 2.09 | 26.7K | 168,579 | — | ↗ |
| 2024-01-18 | ROWLAND LLOYD A | Officer | A-Award | A | Performance Stock Units (PSUs) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2024-01-18 | Ogden Christopher | Officer | A-Award | A | Performance Stock Units (PSUs) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2024-01-18 | McCarthy Sean A. | Director / Officer | A-Award | A | Performance Stock Units (PSUs) | 260,000 | 0.00 | — | 260,000 | — | ↗ |
| 2024-01-18 | Landau Jeffrey B | Officer | A-Award | A | Performance Stock Units (PSUs) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2024-01-18 | Chu Yu-Waye | Officer | A-Award | A | Common Stock | 26,250 | 0.00 | — | 26,250 | — | ↗ |
| 2024-01-18 | BELVIN MARCIA | Officer | A-Award | A | Performance Stock Units (PSUs) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-12-20 | ROWLAND LLOYD A | Officer | S-Sale | D | Common Stock | 4,077 | 1.38 | 5.6K | 97,996 | — | ↗ |
| 2023-12-20 | Ogden Christopher | Officer | S-Sale | D | Common Stock | 1,990 | 1.38 | 2.7K | 48,657 | — | ↗ |
| 2023-12-20 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 13,551 | 1.38 | 18.7K | 454,704 | — | ↗ |
| 2023-12-20 | Landau Jeffrey B | Officer | S-Sale | D | Common Stock | 4,077 | 1.38 | 5.6K | 86,622 | — | ↗ |
| 2023-12-20 | BELVIN MARCIA | Officer | S-Sale | D | Common Stock | 4,077 | 1.38 | 5.6K | 155,124 | — | ↗ |
| 2023-12-17 | ROWLAND LLOYD A | Officer | M-Exempt | A | Common Stock | 11,250 | 0.00 | — | 102,073 | — | ↗ |
| 2023-12-17 | Ogden Christopher | Officer | M-Exempt | A | Common Stock | 6,875 | 0.00 | — | 50,647 | — | ↗ |
| 2023-12-17 | McCarthy Sean A. | Director / Officer | M-Exempt | A | Common Stock | 37,500 | 0.00 | — | 468,255 | — | ↗ |
| 2023-12-17 | Landau Jeffrey B | Officer | M-Exempt | A | Common Stock | 11,250 | 0.00 | — | 90,699 | — | ↗ |
| 2023-12-17 | BELVIN MARCIA | Officer | M-Exempt | A | Common Stock | 11,250 | 0.00 | — | 159,201 | — | ↗ |
| 2023-09-22 | ROWLAND LLOYD A | Officer | S-Sale | D | Common Stock | 5,486 | 1.30 | 7.1K | 80,609 | — | ↗ |
| 2023-09-22 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 14,601 | 1.30 | 19.0K | 430,755 | — | ↗ |
| 2023-09-22 | Landau Jeffrey B | Officer | S-Sale | D | Common Stock | 4,119 | 1.30 | 5.4K | 76,379 | — | ↗ |
| 2023-09-22 | BELVIN MARCIA | Officer | S-Sale | D | Common Stock | 4,119 | 1.30 | 5.4K | 147,951 | — | ↗ |
| 2023-09-20 | ROWLAND LLOYD A | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 86,095 | — | ↗ |
| 2023-09-20 | McCarthy Sean A. | Director / Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 445,356 | — | ↗ |
| 2023-09-20 | Landau Jeffrey B | Officer | A-Award | A | Common Stock | 11,250 | 0.00 | — | 80,498 | — | ↗ |
| 2023-09-20 | BELVIN MARCIA | Officer | A-Award | A | Common Stock | 11,250 | 0.00 | — | 152,070 | — | ↗ |
| 2023-07-19 | Chu Yu-Waye | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 1.82 | 682.5K | 375,000 | — | ↗ |
| 2023-06-14 | Young Matthew P. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.57 | 39.3K | 25,000 | — | ↗ |
| 2023-06-14 | Mohindru Mani | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.57 | 39.3K | 25,000 | — | ↗ |
| 2023-06-14 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.57 | 39.3K | 25,000 | — | ↗ |
| 2023-06-14 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.57 | 39.3K | 25,000 | — | ↗ |
| 2023-06-14 | Gilbert Halley E | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.57 | 39.3K | 25,000 | — | ↗ |
| 2023-06-14 | Ashworth Alan | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.57 | 39.3K | 25,000 | — | ↗ |
| 2023-05-19 | McCarthy Sean A. | Director / Officer | M-Exempt | A | Common Stock | 16,535 | 1.57 | 26.0K | 405,356 | — | ↗ |
| 2023-03-29 | Jones Elaine V | Director | P-Purchase | A | Common Stock | 5,000 | 1.55 | 7.8K | 5,142 | — | ↗ |
| 2023-03-22 | BELVIN MARCIA | Officer | — | D | Stock Option (Right to Buy) | 135,000 | 4.13 | 557.6K | 0 | — | ↗ |
| 2023-03-16 | ROWLAND LLOYD A | Officer | S-Sale | D | Common Stock | 2,037 | 1.98 | 4.0K | 71,095 | — | ↗ |
| 2023-03-16 | Peterson Amy C. | Officer | S-Sale | D | Common Stock | 4,257 | 1.98 | 8.4K | 58,433 | — | ↗ |
| 2023-03-16 | Ogden Christopher | Officer | S-Sale | D | Common Stock | 516 | 1.98 | 1.0K | 37,772 | — | ↗ |
| 2023-03-16 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 7,121 | 1.88 | 13.4K | 388,821 | — | ↗ |
| 2023-03-16 | Landau Jeffrey B | Officer | S-Sale | D | Common Stock | 1,477 | 1.98 | 2.9K | 69,248 | — | ↗ |
| 2023-03-16 | Campoy Carlos | Officer | S-Sale | D | Common Stock | 1,748 | 1.98 | 3.5K | 38,224 | — | ↗ |
| 2023-02-02 | ROWLAND LLOYD A | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 73,132 | — | ↗ |
| 2023-02-02 | Ogden Christopher | Officer | A-Award | A | Performance Stock Units (PSUs) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-02-02 | McCarthy Sean A. | Director / Officer | A-Award | A | Performance Stock Units (PSUs) | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2023-02-02 | Landau Jeffrey B | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 70,725 | — | ↗ |
| 2022-08-10 | ROWLAND LLOYD A | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 0.00 | — | 135,000 | — | ↗ |
| 2022-08-10 | Ogden Christopher | Officer | A-Award | A | Performance Stock Units (PSUs) | 13,750 | 0.00 | — | 13,750 | — | ↗ |
| 2022-08-10 | McCarthy Sean A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 1.59 | 715.5K | 450,000 | — | ↗ |
| 2022-08-10 | Landau Jeffrey B | Officer | A-Award | A | Performance Stock Units (PSUs) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-07-19 | ROWLAND LLOYD A | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 49,291 | — | ↗ |
| 2022-07-19 | Peterson Amy C. | Officer | S-Sale | D | Common Stock | 7,463 | 1.42 | 10.6K | 62,690 | — | ↗ |
| 2022-07-19 | McCarthy Sean A. | Officer | S-Sale | D | Common Stock | 14,911 | 1.42 | 21.2K | 290,942 | — | ↗ |
| 2022-07-19 | Landau Jeffrey B | Officer | S-Sale | D | Common Stock | 4,206 | 1.42 | 6.0K | 30,725 | — | ↗ |
| 2022-07-19 | HANNAH ALISON L. | Officer | S-Sale | D | Common Stock | 5,602 | 1.42 | 8.0K | 31,898 | — | ↗ |
| 2022-07-19 | Campoy Carlos | Officer | S-Sale | D | Common Stock | 3,949 | 1.42 | 5.6K | 39,972 | — | ↗ |
| 2022-06-15 | Young Matthew P. | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-15 | Mohindru Mani | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-15 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-15 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-15 | Gilbert Halley E | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-15 | GLUCK FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-06-15 | Ashworth Alan | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-05-09 | McCarthy Sean A. | Director / Officer | M-Exempt | A | Common Stock | 24,189 | 0.95 | 22.9K | 265,853 | — | ↗ |
| 2022-03-23 | Landau Jeffrey B | Officer | — | D | Stock Option (Right to Buy) | 97,644 | 4.13 | 403.3K | 0 | — | ↗ |
| 2022-02-14 | Ogden Christopher | Officer | — | D | Common Stock | 0 | 0.00 | — | 7,288 | — | ↗ |
| 2022-02-02 | ROWLAND LLOYD A | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 34,291 | — | ↗ |
| 2022-02-02 | Peterson Amy C. | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 46,421 | — | ↗ |
| 2022-02-02 | McCarthy Sean A. | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 174,922 | — | ↗ |
| 2022-02-02 | HANNAH ALISON L. | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 4.13 | 557.6K | 135,000 | — | ↗ |
| 2022-02-02 | Campoy Carlos | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 28,921 | — | ↗ |
| 2021-10-24 | ROWLAND LLOYD A | Officer | A-Award | A | Performance Stock Units (PSUs) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2021-10-24 | Peterson Amy C. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.34 | 267.0K | 50,000 | — | ↗ |
| 2021-10-24 | McCarthy Sean A. | Director / Officer | A-Award | A | Performance Stock Units (PSUs) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2021-10-24 | HANNAH ALISON L. | Officer | A-Award | A | Performance Stock Units (PSUs) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2021-10-24 | Campoy Carlos | Officer | A-Award | A | Performance Stock Units (PSUs) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2021-09-29 | Ashworth Alan | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 4.93 | 197.2K | 40,000 | — | ↗ |
| 2021-08-11 | McCarthy Sean A. | Director / Officer | M-Exempt | A | Common Stock | 92,113 | 1.13 | 104.4K | 99,922 | — | ↗ |
| 2021-06-16 | Young Matthew P. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.13 | 142.6K | 20,000 | — | ↗ |
| 2021-06-16 | SCARLETT JOHN A | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.13 | 142.6K | 20,000 | — | ↗ |
| 2021-06-16 | Mohindru Mani | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.13 | 142.6K | 20,000 | — | ↗ |
| 2021-06-16 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.13 | 142.6K | 20,000 | — | ↗ |
| 2021-06-16 | McCarthy Sean A. | Director / Officer | S-Sale | D | Common Stock | 100,000 | 7.04 | 704.5K | 93,118 | — | ↗ |
| 2021-06-16 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.13 | 142.6K | 20,000 | — | ↗ |
| 2021-06-16 | Gilbert Halley E | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.13 | 142.6K | 20,000 | — | ↗ |
| 2021-06-16 | GLUCK FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 7.13 | 142.6K | 20,000 | — | ↗ |
| 2021-06-14 | McCarthy Sean A. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 30 | 1.13 | 34.02 | 92,113 | — | ↗ |
| 2021-05-31 | Peterson Amy C. | Officer | A-Award | A | Common Stock | 3,320 | 6.09 | 20.2K | 6,421 | — | ↗ |
| 2021-05-31 | Campoy Carlos | Officer | A-Award | A | Common Stock | 3,320 | 6.09 | 20.2K | 6,421 | — | ↗ |
| 2021-03-31 | McCarthy Sean A. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 1.13 | 113.4K | 92,143 | — | ↗ |
| 2021-02-27 | McCarthy Sean A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 7.85 | 1.57M | 200,000 | — | ↗ |
| 2021-02-26 | ROWLAND LLOYD A | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 7.85 | 981.3K | 125,000 | — | ↗ |
| 2021-02-26 | Peterson Amy C. | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 7.85 | 1.96M | 250,000 | — | ↗ |
| 2021-02-26 | McCarthy Sean A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 7.85 | 3.14M | 400,000 | — | ↗ |
| 2021-02-26 | HANNAH ALISON L. | Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 7.85 | 1.37M | 175,000 | — | ↗ |
| 2021-02-26 | Campoy Carlos | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 7.85 | 785.0K | 100,000 | — | ↗ |
| 2021-01-25 | BVF PARTNERS L P/IL | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-23 | McCarthy Sean A. | Director / Officer | M-Exempt | A | Common Stock | 100,000 | 1.13 | 113.4K | 206,894 | — | ↗ |
| 2020-12-18 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock, $0.00001 par value per share | 0 | 0.00 | — | 358,450 | — | ↗ |
| 2020-12-16 | Mohindru Mani | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 7.45 | 298.0K | 40,000 | — | ↗ |
| 2020-11-30 | Peterson Amy C. | Officer | A-Award | A | Common Stock | 3,101 | 6.39 | 19.8K | 3,101 | — | ↗ |
| 2020-11-30 | McCarthy Sean A. | Director / Officer | A-Award | A | Common Stock | 930 | 6.39 | 5.9K | 106,894 | — | ↗ |
| 2020-11-30 | Campoy Carlos | Officer | A-Award | A | Common Stock | 3,101 | 6.39 | 19.8K | 3,101 | — | ↗ |
| 2020-09-21 | McCarthy Sean A. | Director / Officer | M-Exempt | A | Common Stock | 20,500 | 6.61 | 135.6K | 105,964 | — | ↗ |
| 2020-06-17 | Young Matthew P. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 8.35 | 167.0K | 20,000 | — | ↗ |
| 2020-06-17 | SCARLETT JOHN A | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 8.35 | 167.0K | 20,000 | — | ↗ |
| 2020-06-17 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 8.35 | 167.0K | 20,000 | — | ↗ |
| 2020-06-17 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 8.35 | 167.0K | 20,000 | — | ↗ |
| 2020-06-17 | Gilbert Halley E | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 8.35 | 167.0K | 20,000 | — | ↗ |
| 2020-06-17 | GLUCK FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 8.35 | 167.0K | 20,000 | — | ↗ |
| 2020-06-17 | Fuchs Charles S. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 8.35 | 167.0K | 20,000 | — | ↗ |
| 2020-05-29 | McCarthy Sean A. | Director / Officer | A-Award | A | Common Stock | 1,158 | 5.11 | 5.9K | 85,464 | — | ↗ |
| 2020-05-12 | McCarthy Sean A. | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 36,000 | 1.13 | 40.8K | 292,143 | — | ↗ |
| 2020-04-27 | Gilbert Halley E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-03-23 | Campoy Carlos | Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 4.93 | 1.73M | 350,000 | — | ↗ |
| 2020-02-14 | ROWLAND LLOYD A | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 7.13 | 713.0K | 100,000 | — | ↗ |
| 2020-02-14 | Peterson Amy C. | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 7.13 | 178.3K | 25,000 | — | ↗ |
| 2020-02-14 | McCarthy Sean A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 500,000 | 7.13 | 3.57M | 500,000 | — | ↗ |
| 2020-02-14 | Knifsend Robin | Officer | A-Award | A | Stock Option (right to buy) | 34,000 | 7.13 | 242.4K | 34,000 | — | ↗ |
| 2020-02-14 | Kavanaugh William Michael | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 7.13 | 855.6K | 120,000 | — | ↗ |
| 2020-02-03 | HANNAH ALISON L. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.71 | 1.93M | 250,000 | — | ↗ |
| 2019-11-30 | McCarthy Sean A. | Director / Officer | A-Award | A | Common Stock | 1,080 | 5.32 | 5.7K | 84,306 | — | ↗ |
| 2019-10-15 | Peterson Amy C. | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 7.16 | 2.86M | 400,000 | — | ↗ |
| 2019-10-14 | Peterson Amy C. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-30 | McCarthy Sean A. | Director / Officer | G-Gift | D | Common Stock | 4,500 | 0.00 | — | 7,809 | — | ↗ |
| 2019-06-19 | Young Matthew P. | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 11.31 | 158.3K | 14,000 | — | ↗ |
| 2019-06-19 | SCARLETT JOHN A | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 11.31 | 158.3K | 14,000 | — | ↗ |
| 2019-06-19 | Meyers James R | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 11.31 | 158.3K | 14,000 | — | ↗ |
| 2019-06-19 | Jones Elaine V | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 11.31 | 158.3K | 14,000 | — | ↗ |
| 2019-06-19 | GLUCK FREDERICK W | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 11.31 | 158.3K | 14,000 | — | ↗ |
| 2019-06-19 | Fuchs Charles S. | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 11.31 | 158.3K | 14,000 | — | ↗ |
| 2019-05-31 | ROWLAND LLOYD A | Officer | A-Award | A | Common Stock | 1,812 | 8.21 | 14.9K | 11,791 | — | ↗ |
| 2019-05-31 | McCarthy Sean A. | Director / Officer | A-Award | A | Common Stock | 695 | 8.21 | 5.7K | 83,226 | — | ↗ |
| 2019-05-31 | Knifsend Robin | Officer | A-Award | A | Common Stock | 1,812 | 8.21 | 14.9K | 2,791 | — | ↗ |
| 2019-05-22 | Knifsend Robin | Officer | — | D | Common Stock | 0 | 0.00 | — | 979 | — | ↗ |
| 2019-05-01 | Jones Elaine V | Director | A-Award | A | Stock Option (right to buy) | 28,000 | 9.35 | 261.8K | 28,000 | — | ↗ |
| 2019-04-08 | GLUCK FREDERICK W | Director | G-Gift | D | Common Stock | 3,900 | 0.00 | — | 267,743 | — | ↗ |
| 2019-03-04 | ROWLAND LLOYD A | Officer | P-Purchase | A | Common Stock | 9,000 | 10.33 | 93.0K | 9,979 | — | ↗ |
| 2019-01-25 | ROWLAND LLOYD A | Officer | A-Award | A | Stock Option (right to buy) | 54,900 | 16.85 | 925.1K | 54,900 | — | ↗ |
| 2019-01-25 | RAY DEBANJAN | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 16.85 | 1.52M | 90,000 | — | ↗ |
| 2019-01-25 | McCarthy Sean A. | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 16.85 | 5.06M | 300,000 | — | ↗ |
| 2019-01-25 | Kavanaugh William Michael | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 16.85 | 1.52M | 90,000 | — | ↗ |
| 2019-01-25 | HUMPHREY RACHEL | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 16.85 | 1.52M | 90,000 | — | ↗ |
| 2018-12-20 | Meyers James R | Director | A-Award | A | Stock Option (right to buy) | 28,000 | 14.04 | 393.1K | 28,000 | — | ↗ |
| 2018-12-12 | RAY DEBANJAN | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 1.45 | 4.3K | 7,220 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-187.9K
Shares Outstanding
170.25M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | 675.3K | — | 1.15M | 2.16M | 749.6K | 5.0K | 4.74M | 69.82% | ↗ |
| 2 | 2025 | Rachael Lester Senior Vice President and Chief Business Officer | 77.0K | 120.0K | — | 1.99M | 44.5K | — | 2.23M | 89.19% | ↗ |
| 3 | 2025 | Chris Ogden Senior Vice President, and Chief Financial Officer | 478.7K | — | 224.9K | 446.4K | 387.7K | 5.0K | 1.54M | 43.52% | ↗ |
| 4 | 2024 | Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | 675.3K | — | 588.0K | 484.5K | — | 5.0K | 1.75M | 61.19% | ↗ |
| 5 | 2024 | Chris Ogden Senior Vice President, and Chief Financial Officer | 424.7K | — | 219.3K | 265.4K | — | 5.0K | 914.3K | 53.01% | ↗ |
| 6 | 2024 | Wayne Chu, M.D. Senior Vice President and Chief Medical Officer | 491.9K | — | 170.1K | 141.3K | — | 5.0K | 808.4K | 38.52% | ↗ |
| 7 | 2023 | Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | 652.1K | — | 1.05M | 533.2K | 371.9K | 5.0K | 2.61M | 60.59% | ↗ |
| 8 | 2023 | Marcia P. Belvin, Ph.D. Senior Vice President, and Chief Scientific Officer | 459.8K | — | 402.3K | 169.3K | 170.0K | 5.0K | 1.21M | 47.38% | ↗ |
| 9 | 2023 | Jeff Landau Senior Vice President and Chief Business Officer | 415.7K | — | 297.9K | 169.3K | 160.0K | 5.0K | 1.05M | 44.58% | ↗ |
| 10 | 2022 | Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | 622.9K | — | 429.0K | 1.56M | 397.6K | 5.0K | 3.01M | 65.97% | ↗ |
| 11 | 2022 | Amy Peterson, M.D. Former President and Chief Operating Officer | 445.8K | — | 165.2K | 490.0K | — | 747.1K | 1.85M | 35.45% | ↗ |
| 12 | 2022 | Carlos Campoy Former Senior Vice President and Chief Financial Officer | 349.5K | — | 92.9K | 330.7K | — | 647.1K | 1.42M | 29.83% | ↗ |
| 13 | 2022 | Lloyd A. Rowland Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | 425.2K | — | 128.7K | 467.7K | 178.5K | 5.0K | 1.21M | 49.49% | ↗ |
| 14 | 2022 | Jeff Landau Senior Vice President and Chief Business Officer | 393.3K | — | 103.0K | 376.2K | 183.4K | 5.0K | 1.06M | 45.17% | ↗ |
| 15 | 2021 | Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | 615.8K | — | 427.2K | 2.93M | 359.5K | 5.0K | 4.34M | 77.41% | ↗ |
| 16 | 2021 | Amy Peterson, M.D. Former President and Chief Operating Officer | 520.6K | — | 213.6K | 1.25M | 266.8K | 5.0K | 2.25M | 64.82% | ↗ |
| 17 | 2021 | Amy Peterson, M.D. President, Chief Operating Officer | 520.6K | — | 213.6K | 1.25M | 266.8K | 5.0K | 2.25M | 64.82% | ↗ |
| 18 | 2021 | Jeff Landau Senior Vice President and Chief Business Officer | 274.9K | 115.0K | 120.2K | 1.13M | 112.7K | 5.0K | 1.76M | 71.08% | ↗ |
| 19 | 2021 | Alison Hannah Senior Vice President and Chief Medical Officer | 464.4K | — | 160.2K | 887.2K | 190.4K | 5.0K | 1.71M | 61.35% | ↗ |
| 20 | 2021 | Lloyd A. Rowland Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | 417.8K | — | 160.2K | 667.5K | 171.3K | 5.0K | 1.42M | 58.22% | ↗ |
| 21 | 2021 | Carlos Campoy Senior Vice President, Chief Financial Officer | 477.6K | — | 160.2K | 557.7K | 195.8K | 5.0K | 1.40M | 51.41% | ↗ |
| 22 | 2021 | Carlos Campoy Former Senior Vice President and Chief Financial Officer | 477.6K | — | 160.2K | 557.7K | 195.8K | 5.0K | 1.40M | 51.41% | ↗ |
| 23 | 2020 | Sean A. McCarthy, D. Phil. President, Chief Executive Officer and Chairman of the Board of Directors | 595.0K | — | — | 1.89M | 357.0K | 5.0K | 2.85M | 66.42% | ↗ |
| 24 | 2020 | Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | 595.0K | — | — | 1.89M | 357.0K | 5.0K | 2.85M | 66.42% | ↗ |
| 25 | 2020 | Carlos Campoy Senior Vice President, Chief Financial Officer | 360.1K | — | — | 972.9K | 144.7K | 264.0K | 1.74M | 55.86% | ↗ |
| 26 | 2020 | Alison Hannah Senior Vice President and Chief Medical Officer | 412.5K | — | — | 1.02M | 197.1K | 45.0K | 1.68M | 60.99% | ↗ |
| 27 | 2020 | W. Michael Kavanaugh, M.D. Former Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | 423.4K | — | — | 506.2K | — | 7.10M | 1.64M | 30.87% | ↗ |
| 28 | 2020 | Lloyd A. Rowland Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | 403.7K | — | — | 378.6K | 161.5K | 9.7K | 953.4K | 39.71% | ↗ |
| 29 | 2020 | Amy Peterson, M.D. President, Chief Operating Officer | 503.0K | — | — | 94.6K | 301.8K | — | 899.4K | 10.52% | ↗ |
| 30 | 2020 | Amy Peterson, M.D. Executive Vice President, Chief Development Officer | 503.0K | — | — | 94.6K | 301.8K | — | 899.4K | 10.52% | ↗ |
| 31 | 2019 | Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | 575.0K | — | — | 2.86M | 327.8K | 5.0K | 3.77M | 75.92% | ↗ |
| 32 | 2019 | Sean A. McCarthy, D. Phil. President, Chief Executive Officer and Chairman of the Board of Directors | 575.0K | — | — | 2.86M | 327.8K | 5.0K | 3.77M | 75.92% | ↗ |
| 33 | 2019 | Amy Peterson, M.D. Executive Vice President, Chief Development Officer | 108.0K | — | — | 1.55M | 41.9K | 1.70M | 3.40M | 45.59% | ↗ |
| 34 | 2019 | Amy Peterson, M.D. President, Chief Operating Officer | 108.0K | — | — | 1.55M | 41.9K | 1.70M | 3.40M | 45.59% | ↗ |
| 35 | 2019 | Rachel W. Humphrey, M.D. Former Senior Vice President and Chief Medical Officer | 289.8K | — | — | 858.7K | — | 833.9K | 1.87M | 45.88% | ↗ |
| 36 | 2019 | W. Michael Kavanaugh, M.D. Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | 444.5K | — | — | 858.7K | 168.9K | 5.0K | 1.48M | 58.14% | ↗ |
| 37 | 2019 | W. Michael Kavanaugh, M.D. Former Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | 444.5K | — | — | 858.7K | 168.9K | 5.0K | 1.48M | 58.14% | ↗ |
| 38 | 2019 | Lloyd A. Rowland Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | 390.0K | — | — | 523.8K | 132.6K | 51.5K | 1.10M | 47.71% | ↗ |
| 39 | 2019 | Debanjan Ray Former Senior Vice President and Chief Financial Officer | 153.6K | — | — | 858.7K | — | 52.5K | 1.06M | 80.73% | ↗ |
| 40 | 2019 | Alison Hannah Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 41 | 2019 | Carlos Campoy Senior Vice President, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 42 | 2018 | Sean A. McCarthy, D. Phil. President, Chief Executive Officer and Chairman of the Board of Directors | 550.0K | — | — | 4.51M | 412.5K | 5.5K | 5.48M | 82.34% | ↗ |
| 43 | 2018 | Rachel W. Humphrey, M.D. Senior Vice President and Chief Medical Officer | 440.4K | — | — | 1.50M | 220.2K | 125.4K | 2.29M | 65.69% | ↗ |
| 44 | 2018 | Rachel W. Humphrey, M.D. Former Senior Vice President and Chief Medical Officer | 440.4K | — | — | 1.50M | 220.2K | 125.4K | 2.29M | 65.69% | ↗ |
| 45 | 2018 | Debanjan Ray Senior Vice President and Chief Financial Officer | 393.8K | — | — | 1.50M | 196.9K | 5.0K | 2.10M | 71.64% | ↗ |
| 46 | 2018 | Debanjan Ray Former Senior Vice President and Chief Financial Officer | 393.8K | — | — | 1.50M | 196.9K | 5.0K | 2.10M | 71.64% | ↗ |
| 47 | 2018 | Lloyd A. Rowland, Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | 360.0K | — | — | 1.45M | 110.5K | 26.6K | 1.79M | 80.72% | ↗ |
| 48 | 2018 | W. Michael Kavanaugh, M.D. Former Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | 427.4K | — | — | 1.13M | 213.7K | 5.0K | 1.77M | 63.60% | ↗ |
| 49 | 2018 | W. Michael Kavanaugh, M.D. Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | 427.4K | — | — | 1.13M | 213.7K | 5.0K | 1.77M | 63.60% | ↗ |
| 50 | 2018 | Lloyd A. Rowland Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | 360.0K | — | — | 1.45M | 110.5K | 26.6K | 26.6K | 5,445.16% | ↗ |
| 51 | 2018 | Alison Hannah Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 52 | 2018 | Amy Peterson, M.D. Executive Vice President, Chief Development Officer | — | — | — | — | — | — | — | — | ↗ |
| 53 | 2018 | Carlos Campoy Senior Vice President, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 54 | 2017 | Sean A. McCarthy, D. Phil. President and Chief Executive Officer | 500.0K | — | — | 2.28M | 425.0K | 3.5K | 3.21M | 71.11% | ↗ |
| 55 | 2017 | Sean A. McCarthy, D. Phil. President, Chief Executive Officer and Chairman of the Board of Directors | 500.0K | — | — | 2.28M | 425.0K | 3.5K | 3.21M | 71.11% | ↗ |
| 56 | 2017 | Rachel W. Humphrey, M.D. Senior Vice President and Chief Medical Officer | 410.8K | — | — | 884.5K | 244.4K | 69.6K | 1.61M | 54.96% | ↗ |
| 57 | 2017 | Rachel W. Humphrey, M.D. Former Senior Vice President and Chief Medical Officer | 410.8K | — | — | 884.5K | 244.4K | 69.6K | 1.61M | 54.96% | ↗ |
| 58 | 2017 | Debanjan Ray Former Senior Vice President and Chief Financial Officer | 351.1K | — | — | 980.2K | 228.8K | 3.0K | 1.56M | 62.71% | ↗ |
| 59 | 2017 | Debanjan Ray Senior Vice President and Chief Financial Officer | 351.1K | — | — | 980.2K | 228.8K | 3.0K | 1.56M | 62.71% | ↗ |
| 60 | 2017 | Debanjan Ray Chief Financial Officer and Head of Corporate Development | 351.1K | — | — | 980.2K | 228.8K | 3.0K | 1.56M | 62.71% | ↗ |
| 61 | 2017 | Debanjan Ray Chief Financial Officer and Head of Corporate Development Rachel W. Humphrey, M.D., Chief Medical Officer | 410.8K | — | — | 884.5K | 244.4K | — | 1.54M | 57.44% | ↗ |
| 62 | 2017 | W. Michael Kavanaugh, M.D. Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | 410.9K | — | — | 884.5K | 201.4K | 3.0K | 1.50M | 58.97% | ↗ |
| 63 | 2016 | Sean A. McCarthy, D. Phil. President, Chief Executive Officer and Chairman of the Board of Directors | 450.0K | — | — | 2.21M | 292.5K | 6.5K | 2.96M | 74.72% | ↗ |
| 64 | 2016 | Sean A. McCarthy, D. Phil. President and Chief Executive Officer | 450.0K | — | — | 2.21M | 292.5K | 6.5K | 2.96M | 74.72% | ↗ |
| 65 | 2016 | Sean A. McCarthy, D. Phil. President and Chief Executive Officer | 450.0K | — | — | 2.21M | 292.5K | 6.5K | 2.96M | 74.72% | ↗ |
| 66 | 2016 | W. Michael Kavanaugh, M.D. Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development | 395.1K | — | — | 787.0K | 193.6K | 6.6K | 1.38M | 56.93% | ↗ |
| 67 | 2016 | W. Michael Kavanaugh, M.D., Chief Scientific Officer and Head of Research and Non- Clinical Development | 395.1K | — | — | 787.0K | 193.6K | 6.6K | 1.38M | 56.93% | ↗ |
| 68 | 2016 | Debanjan Ray Chief Financial Officer and Head of Corporate Development Rachel W. Humphrey, M.D., Chief Medical Officer | 395.0K | — | — | 639.4K | 193.6K | 34.1K | 1.26M | 50.67% | ↗ |
| 69 | 2016 | Rachel W. Humphrey, M.D. Senior Vice President and Chief Medical Officer | 395.0K | — | — | 639.4K | 193.6K | 34.1K | 1.26M | 50.67% | ↗ |
| 70 | 2016 | Rachel W. Humphrey, M.D., Chief Medical Officer | 395.0K | — | — | 639.4K | 193.6K | 34.1K | 1.26M | 50.67% | ↗ |
| 71 | 2016 | Robert C. Goeltz II Chief Financial Officer and Secretary | 335.0K | — | — | 787.0K | 129.0K | 3.5K | 1.25M | 62.73% | ↗ |
| 72 | 2015 | Sean A. McCarthy, D. Phil. President and Chief Executive Officer | 386.3K | 308.9K | — | 5.56M | 306.0K | 1.8K | 6.56M | 84.71% | ↗ |
| 73 | 2015 | Rachel W. Humphrey, M.D., Chief Medical Officer | 127.9K | 150.0K | — | 4.48M | 67.4K | 11.5K | 4.84M | 92.63% | ↗ |
| 74 | 2015 | Sean A. McCarthy, D. Phil. President and Chief Executive Officer Robert C. Goeltz II Chief Financial Officer and Secretary Rachel W. Humphrey, M.D., Chief Medical Officer W. Michael Kavanaugh, M.D., Chief Scientific Officer and Head of Research and Non- Clinical Development | 197.5K | — | — | 2.15M | 114.1K | 315.00 | 2.47M | 87.35% | ↗ |
| 75 | 2015 | Robert C. Goeltz II Chief Financial Officer and Secretary | 197.5K | — | — | 2.15M | 114.1K | 315.00 | 2.47M | 87.35% | ↗ |
| 76 | 2015 | W. Michael Kavanaugh, M.D., Chief Scientific Officer and Head of Research and Non- Clinical Development | 348.3K | — | — | 1.86M | 197.5K | 2.5K | 2.41M | 77.28% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sean A. McCarthy DPHIL | Chairman & Chief Executive Officer | 1M | — |
| Marcia Belvin | Senior Vice President & Chief Scientific Officer | 634.8K | — |
| Lloyd A. Rowland Jr. | Senior Vice President, General Counsel, Chief Compliance Officer & Secretary | 608.7K | male |
| Yu-Waye Chu | Chief Medical Officer | 496.9K | — |
| Christopher W. Ogden | SVP & Chief Financial Officer | 429.7K | male |
| Leslie Robbins | Senior Vice President of Intellectual Property | — | female |
| Dawn Benson | Senior Vice President of Quality & Product Manufacturing | — | female |
| Rachael Lester | Chief Business Officer & Senior Vice President | — | female |
| Danielle Olander-Moghadassian | Senior Vice President & Chief Human Resources Officer | — | female |
| Stephanie Robertson | Senior Vice President of Alliances & Program Leadership | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTMX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
